Document is current

Article History

Received: 21 December 2023

Accepted: 17 March 2024

First Online: 29 April 2024

Declarations

:

: Akihiko Shimomura reports grant funding from Chugai, AstraZeneca, Daiichi Sankyo, Gilead Sciences, Taiho, Mochida, and Eisai; and honoraria from Chugai, Eli Lilly, AstraZeneca, Gilead Sciences, Exact Sciences, Daiichi Sankyo, Kyowa Kirin, MSD, Pfizer, and Nihon Medi-Physics. Yasuaki Sagara reports honoraria from Pfizer, Daiichi Sankyo, Eli Lilly, MSD, AstraZeneca, Eisai, Chugai, and Nippon Kayaku. Shigehira Saji reports receiving grants and/or contracts from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, and Daiichi Sankyo; honoraria from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho, Ono, and Nippon Kayaku; participation on a data safety monitoring board or advisory board for Chugai/Roche, AstraZeneca, Eli Lilly, Pfizer, Kyowa Kirin, Daiichi Sankyo, and MSD; and executive board membership of Japan Breast Cancer Research Group, Japan Breast Cancer Society, Japanese Society of Medical Oncology, and Breast International Group. Ryo Koto, Masakazu Fujiwara, Yuka Kanemura, and Hiroshi Kitagawa are employed by AstraZeneca K.K., and Hiroshi Kitagawa holds stock options in AstraZeneca K.K.

: The use of deidentified data was performed in compliance with local regulations. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (MINS Ethics Committees; approval number 220209) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

: Informed consent was not required as patient records were anonymized and deidentified prior to access.